Joint Filing AgreementJoint Filing Agreement • May 17th, 2024 • Biotechnology Value Fund L P • Investment advice
Contract Type FiledMay 17th, 2024 Company IndustryThe undersigned hereby agree that the Statement on Schedule 13G dated May 17, 2024 with respect to the Common Stock, $0.001 par value per share, of Pieris Pharmaceuticals, Inc., a Nevada corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • May 2nd, 2022 • Biotechnology Value Fund L P • Investment advice
Contract Type FiledMay 2nd, 2022 Company IndustryThe undersigned hereby agree that the Statement on Schedule 13G dated May 2, 2022 with respect to the Common Stock, $0.001 par value per share of iTeos Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • May 2nd, 2022 • Biotechnology Value Fund L P • Investment advice
Contract Type FiledMay 2nd, 2022 Company IndustryThe undersigned hereby agree that the Statement on Schedule 13G dated May 2, 2022 with respect to the Common Stock, $0.0001 par value per share of IDEAYA Biosciences, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • December 21st, 2020 • Biotechnology Value Fund L P • Investment advice
Contract Type FiledDecember 21st, 2020 Company IndustryThe undersigned hereby agree that the Statement on Schedule 13G dated December 21, 2020 with respect to the shares of Common Stock, par value $0.001, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.